eConsent

Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.

Since it was first instituted in the 1960s, written consent to participate in research studies has undergone very little change other than tightening regulations and increased participant education of their rights.

eConsent accelerates enrollment, increases retention, and reduces site burden. Find out why it’s the way of the future for clinical trials here.

Castor is supporting the next generation of digital therapeutics that can improve patient lives with disease-modifying potential.

eConsent accelerates enrollment, increases retention, and reduces site burden. Learn why it’s the way of the future for clinical trials.

eConsent is imperative for continuing research during the COVID-19 pandemic and beyond, but regulations can vary widely across borders. Download this whitepaper to learn the regulatory stances of 12 countries on the use of eSignature and eConsent in clinical trials.

Castor’s new eConsent platform will improve remote patient recruitment and enrollment as well as access to diverse populations by decentralizing clinical trials.

Castor is using video conferencing to meet participant needs and lower site burden in clinical trials. Find 5 benefits here.

If you are planning on using eConsent in a trial, you’ll need to include it in your IRB submission. Find out what to include here.

Informed consent is a critical aspect of clinical trials. But what criteria must be met? And is there more than one type of consent? Find out here.